Summary & Overview
HCPCS J1559: Injection, Immune Globulin (Hizentra), 100 mg
HCPCS Level II code J1559 identifies a 100 mg unit of Hizentra, a subcutaneous immune globulin preparation used for immunodeficiency and certain autoimmune indications. Nationally, this code matters for accurate drug-specific billing, dose-based reimbursement, and distinguishing subcutaneous immune globulin from intravenous formulations. It also affects charge capture and inventory management for providers administering Hizentra in outpatient and home settings.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find an overview of the code’s clinical context, typical sites of service, and the payers most commonly engaged in coverage and payment decisions. The publication also summarizes available benchmarks for utilization and claims coding practices, notes relevant policy and coverage considerations, and highlights areas where coding specificity can influence payment and reporting.
Content is designed to inform billing staff, revenue cycle leaders, and clinical managers about billing precision for subcutaneous immune globulin, interpretation of HCPCS Level II coding for Hizentra, and where to look for payer policy differences and documentation expectations. Data not available in the input is identified where applicable.
Billing Code Overview
HCPCS Level II code J1559 represents an injection of immune globulin (Hizentra), 100 mg. This code describes administration of subcutaneous immune globulin formulated as Hizentra, dosed and billed in 100 mg units.
Service Type: Subcutaneous immune globulin administration
Typical Site of Service: Outpatient clinics, infusion centers, and home health settings where subcutaneous infusions are performed
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient with primary humoral immunodeficiency presents for replacement therapy with subcutaneous immune globulin (Hizentra). The patient arrives at an infusion clinic or receives home health nursing for administration. After verification of identity, medication, dose calculations (based on weight and orders expressed in mg), and allergy review, the nurse prepares the subcutaneous infusion pump or syringe pump and selects appropriate infusion sites (abdomen, thigh, or upper arm). The nurse performs aseptic skin preparation, inserts subcutaneous infusion needles or catheters, initiates the infusion at a prescribed rate, and monitors the patient for local reactions, headache, fever, or systemic hypersensitivity during and for at least 30 minutes after completion. Documentation includes start/stop times, lot number and amount of J1559 units administered, patient tolerance, and any adverse reactions. Billing uses J1559 reported per 100 mg of Hizentra dispensed and administered, with applicable modifiers to indicate site, professional component, or special circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Not typically appended; use only if payer requires a placeholder |